87 FR 79 pgs. 24320-24321 - Baxter Healthcare Corporation, et al.; Withdrawal of Approval of 14 Abbreviated New Drug Applications
Type: NOTICEVolume: 87Number: 79Pages: 24320 - 24321
Pages: 24320, 24321Docket number: [Docket No. FDA-2022-N-0413]
FR document: [FR Doc. 2022-08744 Filed 4-22-22; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0413]
Baxter Healthcare Corporation, et al.; Withdrawal of Approval of 14 Abbreviated New Drug Applications
AGENCY:
Food and Drug Administration, Health and Human Service (HHS).
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 14 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Approval is withdrawn as of May 25, 2022.
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
[top] The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in §?314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under §?314.150(c) is without prejudice to refiling.
| Application No. | Drug | Applicant |
|---|---|---|
| ANDA 075695 | Butorphanol Tartrate Injection, 1 milligram (mg)/milliliter (mL), and 2 mg/mL | Baxter Healthcare Corporation, One Baxter Pkwy., Deerfield, IL 60015. |
| ANDA 075697 | Butorphanol Tartrate Injection, 2 mg/mL | Do. |
| ANDA 077290 | Oxycodone Hydrochloride (HCl) Tablets, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg | Nesher Pharmaceuticals (USA) LLC, 13910 St. Charles Rock Rd., Bridgeton, MO 63044. |
| ANDA 078564 | Granisetron HCl Injection, Equivalent to (EQ) 1 mg base/mL (EQ 1 mg base/mL) | Morton Grove Pharmaceuticals Inc., 6451 Main St., Morton Grove, IL 60053. |
| ANDA 078565 | Granisetron HCl Injection, EQ 4 mg base/4 mL (EQ 1 mg base/mL) | Do. |
| ANDA 078566 | Granisetron HCl Injection, EQ 0.1 mg base/mL (EQ 0.1 mg base/mL) | Do. |
| ANDA 088342 | Fluoxymesterone Tablets, 10 mg | Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369. |
| ANDA 202032 | Lamivudine Tablets, 150 mg and 300 mg | Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Rd., East Windsor, NJ 08520. |
| ANDA 205322 | Efavirenz Tablets, 600 mg | Do. |
| ANDA 205690 | Choline C-11 Injection, 4-100 millicurie/mL | University of Texas MD Anderson Cancer Center, 1881 East Rd., Unit 1903, Houston, TX 77054. |
| ANDA 207653 | Rosuvastatin Calcium Tablets, EQ 5 mg base, EQ 10 mg base, EQ 20 mg base, EQ 40 mg base | SciRegs International, Inc., 6333 Summercrest Dr., Columbia, MD 21045. |
| ANDA 208199 | Azelastine HCl Metered Spray, 0.2055 mg/spray | Amneal Pharmaceuticals LLC, 50 Horseblock Rd., Brookhaven, NY 11719. |
| ANDA 210032 | Azelastine HCl Metered Spray, 0.2055 mg/spray | Akorn Operating Company LLC, 1925 West Field Ct., Suite 300, Lake Forest, IL 60045. |
| ANDA 211461 | Bosentan Tablets, 62.5 mg and 125 mg | Syneos Health Global Headquarters, 1030 Sync St., Third Floor, Morrisville, NC 27560. |
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of May 25, 2022. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on May 25, 2022 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Dated: April 19, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-08744 Filed 4-22-22; 8:45 am]
BILLING CODE 4164-01-P